Your browser doesn't support javascript.
loading
Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane Integrity.
Smith, Nicholas M; Boissonneault, Katie Rose; Chen, Liang; Petraitis, Vidmantas; Petraitiene, Ruta; Tao, Xun; Zhou, Jieqiang; Lang, Yinzhi; Kavaliauskas, Povilas; Bulman, Zackery P; Holden, Patricia N; Cha, Raymond; Bulitta, Jürgen B; Kreiswirth, Barry N; Walsh, Thomas J; Tsuji, Brian T.
Afiliação
  • Smith NM; Laboratory for Antimicrobial Pharmacodynamics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.
  • Boissonneault KR; New York State Center of Excellence in Life Sciences and Bioinformatics, Buffalo, New York, USA.
  • Chen L; Laboratory for Antimicrobial Pharmacodynamics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.
  • Petraitis V; New York State Center of Excellence in Life Sciences and Bioinformatics, Buffalo, New York, USA.
  • Petraitiene R; Hackensack Meridian Health Center for Discovery and Innovation, Nutley, New Jersey, USA.
  • Tao X; Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA.
  • Zhou J; Transplantation-Oncology Infectious Disease Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA.
  • Lang Y; Transplantation-Oncology Infectious Disease Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA.
  • Kavaliauskas P; Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Floridagrid.15276.37, Orlando, Florida, USA.
  • Bulman ZP; Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Floridagrid.15276.37, Orlando, Florida, USA.
  • Holden PN; Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Floridagrid.15276.37, Orlando, Florida, USA.
  • Cha R; Transplantation-Oncology Infectious Disease Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA.
  • Bulitta JB; Department of Pharmacy Practice, University of Illinois Chicago, Chicago, Illinois, USA.
  • Kreiswirth BN; Laboratory for Antimicrobial Pharmacodynamics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.
  • Walsh TJ; New York State Center of Excellence in Life Sciences and Bioinformatics, Buffalo, New York, USA.
  • Tsuji BT; Laboratory for Antimicrobial Pharmacodynamics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.
Antimicrob Agents Chemother ; 66(9): e0052722, 2022 09 20.
Article em En | MEDLINE | ID: mdl-35924913
Metallo-ß-lactamase (MBL)-producing Gram-negative bacteria cause infections associated with high rates of morbidity and mortality. Currently, a leading regimen to treat infections caused by MBL-producing bacteria is aztreonam combined with ceftazidime-avibactam. The purpose of the present study was to evaluate and rationally optimize the combination of aztreonam and ceftazidime-avibactam with and without polymyxin B against a clinical Klebsiella pneumoniae isolate producing NDM-1 and CTX-M by use of the hollow fiber infection model (HFIM). A novel de-escalation approach to polymyxin B dosing was also explored, whereby a standard 0-h loading dose was followed by maintenance doses that were 50% of the typical clinical regimen. In the HFIM, the addition of polymyxin B to aztreonam plus ceftazidime-avibactam significantly improved bacterial killing, leading to eradication, including for the novel de-escalation dosing strategy. Serial samples from the growth control and monotherapies were explored in a Galleria mellonella virulence model to assess virulence changes. Weibull regression showed that low-level ceftazidime resistance and treatment with monotherapy resulted in increased G. mellonella mortality (P < 0.05). A neutropenic rabbit pneumonia model demonstrated that aztreonam plus ceftazidime-avibactam with or without polymyxin B resulted in similar bacterial killing, and these combination therapies were statistically significantly better than monotherapies (P < 0.05). However, only the polymyxin B-containing combination therapy produced a statistically significant decrease in lung weights (P < 0.05), indicating a decreased inflammatory process. Altogether, adding polymyxin B to the combination of aztreonam plus ceftazidime-avibactam for NDM- and CTX-M-producing K. pneumoniae improved bacterial killing effects, reduced lung inflammation, suppressed resistance amplification, and limited virulence changes.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ceftazidima / Klebsiella pneumoniae Limite: Animals Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ceftazidima / Klebsiella pneumoniae Limite: Animals Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos